2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Ovarian Neoplasms
2
Myelodysplastic Syndromes
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Carcinoma
2
Sezary Syndrome
1
Sarcoma, Synovial
1
Recurrence
1
Rectal Neoplasms
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Lymphoma, Non-Hodgkin
1
Liposarcoma, Myxoid
1
Leukemia, Myeloid
1
Hodgkin Disease
1
HIV Infections
1
Graft vs Host Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
Temozolomide
159
Bevacizumab
69
Radiotherapy
68
Magnetic Resonance Spectroscopy
68
Irinotecan
31
Surgical Procedures, Operative
27
Radiation
24
Carboplatin
23
Specimen Handling
20
Carmustine
20
Blood Specimen Collection
20
Nivolumab
19
Aminolevulinic Acid
18
Biopsy
17
Lomustine
16
pembrolizumab
13
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
13
trametinib
12
fluorodopa F 18
12
X-Rays
12
Radiosurgery
12
Erlotinib Hydrochloride
12
Topotecan
11
Everolimus
11
Magnetic Resonance Imaging
10
IL13-PE38
10
dabrafenib
9
Etoposide
9
Drug Therapy
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
interferon gamma-1b
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled